Adrienne Farid
Fortuna: 612 845 $ al 31/05/2026
Fortuna: 612 845 $ al 31/05/2026
Adrienne Farid worked at Roche Pharmaceuticals, Inc. from 1995 to 2011 as Global Head-Project & Portfolio Management.
From 2014 to 2017, worked at Celgene Corp.
as VP-Project Leadership.
Served as Director at Carisma Therapeutics, Inc. Worked at Century Therapeutics, Inc. from 2021 to 2025 as Chief Development Officer & Head-Early Development from 2024 to 2025.
Education includes a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Barnard College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/03/2026 | 250.141 ( 0,14 % ) | 612 845 $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Director de Operaciones | 01/10/2024 |
| CELGENE | Corporate Officer/Principal | 01/07/2017 |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Corporate Officer/Principal | 01/01/2011 |
| CARISMA THERAPEUTICS, INC. | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Barnard College
Barnard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.